548 active trials 269 recruiting 192 Phase 3 53 disease areas 133 changes in 30 days
66 trials changed in the last 30 days: 0 stopped, 26 with notable changes, 40 with minor changes only.
Primary completion pushed from Jun 4, 2027 to Apr 6, 2028
AstraZenecaPhase 3 NCT07775404 Registry history of NCT07775404 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Feb 28, 2029 to Dec 30, 2029
AstraZenecaNot specified NCT06544629 Registry history of NCT06544629 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from May 14, 2027 to Jan 10, 2028
Also in this update: Completion pushed from Aug 4, 2028 to Apr 9, 2029
AstraZenecaPhase 3 NCT06455449 Registry history of NCT06455449 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jul 16, 2027 to Mar 16, 2029
Also in this update: Enrollment increased: 280 → 392 participants; Interventions modified
AstraZenecaPhase 1/2 NCT06005493 Registry history of NCT06005493 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 16, 2030 to Sep 30, 2032
AstraZenecaPhase 4 NCT06651970 Registry history of NCT06651970 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Jun 30, 2027 to Jun 30, 2030
Also in this update: Primary endpoint(s) modified
AstraZenecaNot specified NCT07390240 Registry history of NCT07390240 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 30, 2026 to Apr 30, 2027
AstraZenecaNot specified NCT07315958 Registry history of NCT07315958 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Phase changed: Phase 3 → Phase 2; Primary and study completion moved earlier from Oct 31, 2028 to Aug 30, 2028
AstraZenecaPhase 2 NCT06960577 Registry history of NCT06960577 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Recruitment opened; Trial sites expanded: 45 → 478 locations
AstraZenecaPhase 3 NCT07624305 Registry history of NCT07624305 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Results posted: Sep 25, 2026; Trial completed
AstraZenecaPhase 2 NCT05498155 Registry history of NCT05498155 on ClinicalTrials.gov (opens the registry)
Updated
Primary endpoint(s) modified
Also in this update: Enrollment closed, study ongoing; Trial sites expanded: 18 → 21 locations
AstraZenecaNot specified NCT07446738 Registry history of NCT07446738 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 0 → 45 locations
AstraZenecaPhase 3 NCT07619118 Registry history of NCT07619118 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Primary completion pushed from Sep 30, 2026 to Dec 31, 2026; Completion moved earlier from Jan 30, 2027 to Dec 31, 2026
AstraZenecaNot specified NCT07593196 Registry history of NCT07593196 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 41 → 128 locations
AstraZenecaPhase 3 NCT07691970 Registry history of NCT07691970 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 0 → 8 locations
AstraZenecaNot specified NCT07800754 Registry history of NCT07800754 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 44 → 71 locations
AstraZenecaPhase 3 NCT07751848 Registry history of NCT07751848 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 218 → 227 locations
AstraZenecaPhase 3 NCT07784270 Registry history of NCT07784270 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 0 → 32 locations
AstraZenecaPhase 2 NCT07630714 Registry history of NCT07630714 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment reopened
Also in this update: Enrollment increased: 192 → 315 participants
AstraZenecaNot specified NCT05999877 Registry history of NCT05999877 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment opened
Also in this update: Trial sites expanded: 1 → 20 locations
AstraZenecaNot applicable NCT07718724 Registry history of NCT07718724 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Study completion date changed from estimate of May 31, 2027 to Jul 27, 2026
AstraZenecaPhase 3 NCT03847428 Registry history of NCT03847428 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 44 → 40 locations
AstraZenecaPhase 1/2 NCT06749457 Registry history of NCT06749457 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
AstraZenecaPhase 1 NCT07612813 Registry history of NCT07612813 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Primary and study completion pushed from Sep 23, 2026 to Nov 16, 2026; Final enrollment: 72 participants (planned 136)
AstraZenecaPhase 1 NCT06995820 Registry history of NCT06995820 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
AstraZenecaNot specified NCT07221981 Registry history of NCT07221981 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
AstraZenecaNot specified NCT06646419 Registry history of NCT06646419 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
AstraZenecaPhase 2 NCT06851858 Registry history of NCT06851858 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
AstraZenecaPhase 1 NCT07622433 Registry history of NCT07622433 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Trial sites reduced: 65 → 39 locations; Final enrollment: 159 participants (planned 300)
AstraZenecaNot specified NCT06031805 Registry history of NCT06031805 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Jul 14, 2026 to May 6, 2026; Final enrollment: 48 participants (planned 150)
AstraZenecaNot specified NCT07024680 Registry history of NCT07024680 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 111 participants (planned 250)
AstraZenecaNot specified NCT06380738 Registry history of NCT06380738 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 6, 2026 to Oct 23, 2026
Also in this update: Enrollment increased: 14 → 16 participants
AstraZenecaPhase 2 NCT07017179 Registry history of NCT07017179 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from May 30, 2027 to Jun 30, 2027
AstraZenecaNot specified NCT06175637 Registry history of NCT06175637 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 150 → 166 participants
AstraZenecaPhase 4 NCT06531798 Registry history of NCT06531798 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 247 → 231 locations
Also in this update: Completion moved earlier from Feb 28, 2029 to Nov 12, 2027; Primary completion date changed from estimate of Feb 28, 2029 to Aug 17, 2026
AstraZenecaPhase 3 NCT05984277 Registry history of NCT05984277 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 68 → 82 locations
AstraZenecaPhase 3 NCT07215585 Registry history of NCT07215585 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 150 → 154 locations
AstraZenecaPhase 3 NCT06307665 Registry history of NCT06307665 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 276 → 284 locations
AstraZenecaPhase 3 NCT06878261 Registry history of NCT06878261 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 144 → 147 locations
AstraZenecaPhase 2 NCT07276581 Registry history of NCT07276581 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 24 → 32 participants
AstraZenecaPhase 1 NCT07402915 Registry history of NCT07402915 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 167 → 190 participants
Also in this update: Primary completion date changed from estimate of Aug 3, 2028 to Jun 16, 2026
AstraZenecaPhase 1 NCT05647122 Registry history of NCT05647122 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 468 → 471 locations
AstraZenecaPhase 3 NCT05624450 Registry history of NCT05624450 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 672 → 679 locations
AstraZenecaPhase 3 NCT07761117 Registry history of NCT07761117 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 177 → 183 locations
AstraZenecaPhase 3 NCT07221253 Registry history of NCT07221253 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 295 → 300 locations
AstraZenecaPhase 3 NCT06627647 Registry history of NCT06627647 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 228 → 235 locations
AstraZenecaPhase 3 NCT06549595 Registry history of NCT06549595 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 325 → 328 locations
AstraZenecaPhase 3 NCT06692738 Registry history of NCT06692738 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 953 → 957 locations
AstraZenecaPhase 3 NCT06677060 Registry history of NCT06677060 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 96 → 63 locations
And 5 more changes in the last 30 days
AstraZenecaPhase 2 NCT06824987 Registry history of NCT06824987 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 190 → 195 locations
AstraZenecaPhase 2 NCT07652658 Registry history of NCT07652658 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 23 → 20 locations
AstraZenecaPhase 1 NCT05877599 Registry history of NCT05877599 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 11 → 15 locations
AstraZenecaNot specified NCT07633158 Registry history of NCT07633158 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 16 → 24 locations
AstraZenecaNot specified NCT07607769 Registry history of NCT07607769 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Sep 28, 2026 to Aug 14, 2026
AstraZenecaPhase 2 NCT07143604 Registry history of NCT07143604 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Aug 24, 2026 to Jun 26, 2026
AstraZenecaPhase 3 NCT04711252 Registry history of NCT04711252 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
AstraZenecaPhase 3 NCT07776509 Registry history of NCT07776509 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Jun 30, 2027 to Mar 31, 2027
Also in this update: Primary completion date changed from estimate of Jun 30, 2027 to Jul 10, 2026
AstraZenecaPhase 3 NCT06564844 Registry history of NCT06564844 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 30, 2026 to Dec 30, 2026
AstraZenecaPhase 3 NCT05883644 Registry history of NCT05883644 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Jan 30, 2026 to Nov 30, 2026
AstraZenecaPhase 1 NCT02546661 Registry history of NCT02546661 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Jul 1, 2026 to May 27, 2027
AstraZenecaPhase 2 NCT06040099 Registry history of NCT06040099 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-10-01 | NCT07851025 Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous… | Phase 3 | Recruiting |
| 2026-09-17 | NCT07824622 Study of Safety and PK of AZD0543 in Healthy Adults | Phase 1 | Recruiting |
| 2026-09-14 | NCT07816666 Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of… | Phase 3 | Not Yet Recruiting |
| Phase 1 | 60 | |
| Phase 1/2 | 49 | |
| Phase 2 | 73 | |
| Phase 2/3 | 2 | |
| Phase 3 | 190 | |
| Phase 4 | 14 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06531798 | Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian… | Moderate to Severe COPD | Recruiting | 2026-10-02 |
| NCT07357597 | An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd)… | Stomatitis | Recruiting | 2026-09-30 |
| NCT06651970 | Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL… | Chronic Lymphocytic Leukaemia | Recruiting | 2026-09-24 |
| NCT07073950 | A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate… | Chronic Obstructive Pulmonary Disease | Recruiting | 2026-09-18 |
| NCT06594068 | Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in… | Systemic Lupus Erythematosus | Recruiting | 2026-09-16 |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After… | Non-small Cell Lung Cancer | Recruiting | 2026-08-27 |
| NCT07308574 | Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS | aHUS | Recruiting | 2026-04-20 |
| NCT07221838 | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia… | Generalized Myasthenia Gravis | Recruiting | 2026-04-09 |
| NCT07306949 | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association… | Transthyretin-type Cardiac Amyloidosis | Recruiting | 2026-01-07 |
| NCT03953300 | Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics | Asthma | Active, Not Recruiting | 2026-09-25 |
| NCT06429761 | Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients | BREAST CANCER | Active, Not Recruiting | 2026-09-11 |
| NCT06422689 | Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on… | Asthma | Active, Not Recruiting | 2026-07-16 |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With… | Metastatic Castration-resistant Prostate Cancer | Active, Not Recruiting | 2026-04-21 |
| NCT06610526 | A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease | Chronic Kidney Disease | Active, Not Recruiting | 2026-01-30 |
| Phase 3 | ||||
| NCT06307665 | Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in… | Asthma | Recruiting | 2026-10-09 |
| NCT06878261 | A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With… | Chronic Obstructive Pulmonary Disease (COPD) | Recruiting | 2026-10-09 |
| NCT07215585 | AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL | Large B-cell Lymphoma | Recruiting | 2026-10-09 |
| NCT06023589 | A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in… | Asthma | Recruiting | 2026-10-06 |
| NCT07509151 | Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia… | Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated IGHV | Recruiting | 2026-10-06 |
| NCT07619118 | A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With… | Hypercholesterolaemia | Recruiting | 2026-10-05 |
| NCT05624450 | Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection… | Viral Lung Infection and Acute Respiratory Failure | Recruiting | 2026-10-02 |
| NCT06283966 | A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate… | COPD (Chronic Obstructive Pulmonary Disease) | Recruiting | 2026-10-02 |
| NCT06307652 | Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure… | Heart Failure and Impaired Kidney Function | Recruiting | 2026-10-02 |
| NCT07205822 | A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0… | Breast Cancer | Recruiting | 2026-10-02 |
| NCT07691970 | Rollover Study for Participants Who Have Completed a Previous Clinical Study With… | Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus | Recruiting | 2026-10-02 |
Lung Cancer (89) · Non-Small Cell Lung Cancer (NSCLC) (79) · Breast Cancer (51) · Asthma (31) · Lupus (SLE) (26) · Prostate Cancer (26) · Ovarian Cancer (22) · Leukemia (19) · Gastric Cancer (17) · Liver Cancer (17)